• 1
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 39093918.
  • 2
    Anderson JR,Armitage JO,Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717720.
  • 3
    National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 21122135.
  • 4
    Lukes RJ,Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34( 4 Suppl): 14881503.
  • 5
    Lennert K,Stein H,Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975; 31 ( Suppl 2): 2943.
  • 6
    Harris NL,Jaffe ES,Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group [see comments]. Blood 1994; 84: 13611392.
  • 7
    Jaffe E,Harris N,Stein H,Bardiman J, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumors. Lyon: IARC Press; 2001. pp 352.
  • 8
    Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Rsearch on Cancer; 2008.
  • 9
    Vose J,Armitage J,Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 41244130.
  • 10
    Feldman AL,Law M,Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009; 23: 574580.
  • 11
    Siu LL,Wong KF,Chan JK,Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999; 155: 14191425.
  • 12
    Zettl A,Ott G,Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002; 161: 16351645.
  • 13
    Macon WR,Levy NB,Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: A report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001; 25: 285296.
  • 14
    Iqbal J,Weisenburger DD,Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 10261036.
  • 15
    de Leval L,Rickman DS,Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109: 49524963.
  • 16
    Carbone PP,Kaplan HS,Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 18601861.
  • 17
    Khong PL,Pang CB,Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008; 87: 613621.
  • 18
    Kako S,Izutsu K,Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 16851690.
  • 19
    Bishu S,Quigley JM,Schmitz J, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007; 48: 15311538.
  • 20
    Storto G,Di Giorgio E,De Renzo A, et al. Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br J Haematol 2010; 151: 195197.
  • 21
    Cahu X,Bodet-Milin C,Brissot E, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol 2011; 22: 705711.
  • 22
    Casulo C,Maragulia J,Zelenetz A, et al. FDG-PET in the staging and prognosis of T-cell lymphoma [Abstract]. Ann Oncol 2011; 22 ( Suppl 4):Abstract #228.
  • 23
    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments]. N Engl J Med 1993; 329: 987994.
  • 24
    Gallamini A,Stelitano C,Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 24742479.
  • 25
    Savage KJ,Harris NL,Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 54965504.
  • 26
    Frizzera G,Moran EM,Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974; 1: 10701073.
  • 27
    Mourad N,Mounier N,Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111: 44634470.
  • 28
    Au WY,Pang A,Choy C, et al. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243249.
  • 29
    Suzuki R,Suzumiya J,Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21: 10321040.
  • 30
    Isaacson P,Wright DH. Intestinal lymphoma associated with malabsorption. Lancet 1978; 1: 6770.
  • 31
    Swinson CM,Slavin G,Coles EC,Booth CC. Coeliac disease and malignancy. Lancet 1983; 1: 111115.
  • 32
    Green PH,Fleischauer AT,Bhagat G, et al. Risk of malignancy in patients with celiac disease. Am J Med 2003; 115: 191195.
  • 33
    Delabie J,Holte H,Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011; 118: 148155.
  • 34
    Chott A,Haedicke W,Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998; 153: 14831490.
  • 35
    Deleeuw RJ,Zettl A,Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007; 132: 19021911.
  • 36
    Cooke CB,Krenacs L,Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin [see comments]. Blood 1996; 88: 42654274.
  • 37
    Ochenrider MG,Patterson DJ,Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: Case report and literature review. Clin Lymphoma Myeloma Leuk 2010; 10: 144148.
  • 38
    Abramson JS,Kotton CN,Elias N, et al. Case records of the Massachusetts General Hospital. Case 8–2008. A 33-year-old man with fever, abdominal pain, and pancytopenia after renal transplantation. N Engl J Med 2008; 358: 11761187.
  • 39
    Tey SK,Marlton PV,Hawley CM, et al. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 2008; 83: 330333.
  • 40
    NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkins Lymphomas. (TCEL-1) 2011;Version
  • 41
    Schmitz N,Trumper L,Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 34183425.
  • 42
    Tilly H,Gaulard P,Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997; 90: 37273734.
  • 43
    Brugieres L,Pacquement H,Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 2009; 27: 50565061.
  • 44
    Le Deley MC,Rosolen A,Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28: 39873993.
  • 45
    Advani R,Shustov AR,Brice P, et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A phase 2 study update [Abstract]. Blood 2011; 117:Abstract #443.
  • 46
    Gambacorti-Passerini C,Messa C,Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011; 364: 775776.
  • 47
    Hosing C,Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 2011; 22: 14711477.
  • 48
    de Jong D,Vasmel WL,de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008; 300: 20302035.
  • 49
    Siegert W,Agthe A,Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992; 117: 364370.
  • 50
    de Leval L,Gisselbrecht C,Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2009; 148: 673689.
  • 51
    Joly B,Frenkel V,Gaulard P, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphomas (AITL): Preliminary results in 9 patients treated in a single institution [Abstract]. Blood 2005; 106:Abstrat #2686.
  • 52
    Joly B,Plonquet A,Grare M, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial—A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [Abstract]. J Clin Oncol 2010; 28:Abstract #8049.
  • 53
    Advani R,Horwitz S,Zelenetz A,Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007; 48: 521525.
  • 54
    Bruns I,Fox F,Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005; 19: 19931995.
  • 55
    Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 2008; 19: 396397.
  • 56
    Rentschler J,Herrmann R,Fischer N, et al. Response to lenalidomide in heavily pre-treated angioimmunoblastic T-cell-lymphoma (AITL) [Abstract]. Ann Oncol 2011; 22 ( Suppl 4):Abstract #249.
  • 57
    Marks R,Fan W,Engelhardt M, et al. Long term disease control and overall survival after early dose intensification in T-NHL depend on specific entities [Abstract]. Ann Oncol 2011; 22 ( Suppl 4):Abstract #101.
  • 58
    Kyriakou C,Canals C,Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 218224.
  • 59
    Kyriakou C,Canals C,Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 39513958.
  • 60
    Gallamini A,Zaja F,Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 23162323.
  • 61
    Foss FM,Sjak-Shie A,Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial [Abstract]. J Clin Oncol 2010; 28( 15 Suppl):Abstract #8045.
  • 62
    Kim SJ,Eom HS,Kim JS, et al. The efficacy of bortezomib CHOP in patients with advanced stage T or NK/T cell lymphomas: The results of multicenter phase II study [Abstract]. Blood 2010; 116(21):Abstract #1791.
  • 63
    Escalon MP,Liu NS,Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M. D. Anderson Cancer Center experience. Cancer 2005; 103: 20912098.
  • 64
    Gisselbrecht C,Gaulard P,Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 7682.
  • 65
    Corazzelli G,Frigeri F,Marcacci G, et al. Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-cell/NK lymphomas: A phase II trial [Abstract]. Blood 2010; 116:Abstract #2829.
  • 66
    d'Amore F,Relander T,Lauritzsen GF, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)—Overall and subtype-specific results of a phase II study from Nordic lymphoma group [Abstract]. Haematologica 2009; 94 ( Suppl 2):Abstract #437.
  • 67
    Relander T,Lauritzsen GF,Jantunen E, et al. Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive inducation chemotherapy and autologous stem cell transplantation (ASCT): A prospective study by the Nordic Lymphoma Group (NLG-T-01)[Abstract]. Blood 2010; 116:Abstract #3566.
  • 68
    O'Connor OA,Pro B,Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 11821189.
  • 69
    Piekarz RL,Frye R,Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 58275834.
  • 70
    Dueck G,Chua N,Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010; 116: 45414548.
  • 71
    William BM,Hohenstein M,Loberiza FR, et al. Phase I/II study of dasatinib in relapsed or refractory non-Hodgin's lymphoma (NHL) [Abstract]. Blood 2010; 116: 131 Abstract #288.
  • 72
    Friedberg J,Mahadevan D,Jung JA, et al. Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of auror A kinase (AAK), in patients (pts) with aggressive B- an T-Cell non-Hodgkin lymphoma (NHL) [Abstract]. Blood 2011; 118:46 Abstract #95.
  • 73
    Li YX,Yao B,Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181189.
  • 74
    Drenou B,Lamy T,Amiot L, et al. CD3− CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997; 89: 29662974.
  • 75
    Rodriguez J,Romaguera JE,Manning J, et al. Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma 2000; 39: 139144.
  • 76
    Nagafuji K,Fujisaki T,Arima F,Ohshima K. L-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 447450.
  • 77
    Yamaguchi M,Kwong YL,Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol 2011; 29: 44104416.
  • 78
    Gale J,Simmonds PD,Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center [In Process Citation]. J Clin Oncol 2000; 18: 795.
  • 79
    Sieniawski M,Angamuthu N,Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010; 115: 36643670.
  • 80
    Belhadj K,Reyes F,Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 42614269.
  • 81
    Jaeger G,Bauer F,Brezinschek R, et al. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008; 19: 10251026.
  • 82
    Grigg AP. 2′-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2001; 42: 797799.
  • 83
    Machino T,Okoshi Y,Kaneko S, et al. Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation. Bone Marrow Transplant 2007; 39: 513514.
  • 84
    Falchook GS,Vega F,Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment. Ann Oncol 2009; 20: 10801085.